ArticleJournal of oral biology and craniofacial research
Effectiveness of liquid Platelet Rich Fibrin (i-PRF) in treatment of Temporomandibular disorders (TMD)- A randomized non-blinded, 2 arm, parallel trial.
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: 1. To evaluate role of growth factors, mainly i-PRF in treatment of Temporomandibular disorders (TMD). 2. To compare effectiveness of i-PRF in pain reduction with conservative treatments. Material and method: patients were divided randomly into control and test (30 each group). Each underwent MRI and only after confirming disc related problem, treatment was started, control group was kept on conservative treatment, whereas in test group, injectable platelet rich plasma (iPRF) was injected in the joint space. The follow-up period of both the groups was 6 months. Results: In test group (subjects who received iPRF injection) 30.4% showed VAS score 0 at day 15, and at 6 months about 78.3% of subjects show VAS score 0. In the control group, at day 15 for control group, 32% of the subjects showed VAS score 0, and at 6 months about 29% subjects show VAS score 0. Similarly, in the test group, pre-operatively there are 23.9% of participants in stage I (wilkes classification) category of TMJ pain and 17.4% in the stage V category, at the end of 6 months, this number was reduced to 0% in the stage V category and 82.6% in stage I category. Conclusion: iPRF works for the pain management of TMJ and has a long-lasting effect on the repair and regeneration of the disc and should be considered as the primary treatment modality for TMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.